ANALYZE THE TREATMENT REGIMENS AND THROMBOSIS PROPHYLAXIS USED IN CORONARY ARTERY INTERVENTION AT INTERVENTIONAL CARDIOLOGY UNIT IN CAN THO CENTRAL GENERAL HOSPITAL
Objective: The study was conducted to analyze the rationality of treatment regimens and thrombosis prophylaxis used in coronary artery intervention to compare to guidelines for treatment according to VNHA and recommendation of ACC/AHA at Interventional cardiology in Can Tho Central General Hospital.
Methods: The cross-sectional study was based on the data collected from entire medical records of patients at Interventional cardiology in Can Tho Central General Hospital from August 2017 to February 2018. The rationality of the antithrombotic regimen used at the Hospital is assessed through criteria such as medical combination, dosage, time to take medicine, clinical trials during the treatment.
Results: The study found that 95.6% and 90.7% were suitable for medical combination before and after PCI; 100% fit for the use of medicine; and 100% was suitable for antithrombotic agents and clinical trials during treatment time; in terms of dosage, the result showed that entrance and maintenance were 84.9% and 100% for aspirin respectively; 71.7% and 100% for clopidogrel; 100% and 94.7% for ticagrelor; 90.2-92.8% and 98.1% for enoxaparin; especially, heparin-100% anticoagulant was appropriate to recommend.
Conclusion: The study showed that treatment regimens and thrombosis prophylaxis in percutaneous coronary intervention at Interventional cardiology in Can Tho Central General Hospital were quite suitable compared to the recommendations of the Heart Association. The results from the study are a scientific basis for the Hospital to maintain or consider adjustments to improve the quality of treatment, ensure the effectiveness and safety of patients.
2. Cardio-vascular society of Viet Nam. Recommendation of the vietnam society of cardiology on percutaneous coronary intervention. 1st ed. Ho Chi Minh City Medical Publishing House; 2008.
3. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-e228.
4. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2007;116:e148-304.
5. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2008;51:210-47.
6. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2016;134:e123-55.
7. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 2011;124:e574-651.
8. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.
9. Hai-Ha D. Assess the situation of anticoagulant use in the treatment of coronary artery diasease at Heart Institute, Bach Mai hospital. Master thesis, Pharmacologic department, Ha Noi Medical University, Vietnam; 2010.
10. Hong Loan N. Investigate the situation of using anti-thrombotic drugs and anticoagulants used in the treatment of coronary artery diasease at Heart Institute, Central Military Hospital 108. Master thesis, Pharmacologic department, Ha Noi Medical University, Vietnam; 2013.
11. Tuyet Nhung MT. Investigate the situation of using anti-thrombotic drugs in the interventional cardiology and orthopedics department, Cho Ray hospital. Master thesis, Medical Department, University of Medicine and Pharmacy at Ho Chi Minh city, Vietnam; 2015.
12. Hieu Nhan D. Antiplatelet in clinical practice. 1st ed. Ho Chi Minh City: Ho Chi Minh City Medical Publishing House; 2017.
13. Hendra Wana Na, Iwan D, Erna K. Effectiveness of ticagrelor compared to clopidogrel in reducing the risk of major adverse cardiovascular events in patients with coronary heart disease after percutaneous coronary intervention. Int J Pharm Pharm Sci 2017;9:178-83.
14. Askari AT, Lincoff AM. Antithrombotic drug therapy in cardiovascular disease. 1st ed. Berlin: Springer Science and Business Media; 2010.
15. Mulukutla SR, Marroquin OC, Vlachos HA, Selzer F, Toma C, Kip KE, et al. Benefit of long-term dual antiplatelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol 2013;111:486-92.
This work is licensed under a Creative Commons Attribution 4.0 International License.